AACR-2025

AACR-2025
April 25-30, 2025
Chicago, IL

American Association for Cancer Research.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (3)

    Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +/- carboplatin in the EVOKE-02 study of non-small cell lung cancer

    • Author(s): Patel, JD
    • trodelvy
    • Oncology
    • Poster

    Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01

    • Author(s): Garassino, MC
    • trodelvy
    • Oncology
    • Poster

    Circulating tumor DNA (ctDNA) mutation analysis at baseline (BSL) and end of treatment (EOT) with sacituzumab govitecan (SG) and clinical impact on efficacy in patients (pts) with HR+/HER2- metastatic breast cancer (mBC): Biomarker results from TROPiCS-02

    • Author(s): Rugo, HS
    • trodelvy
    • Oncology
    • Poster